The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Novo Bolsters Wegovy Label in Japan with CV Outcome Data
March 6, 2025
- AZ Wins Certification to Allow Use of Pseudonymized Medical Info
March 6, 2025
- DMD Cell Therapy Accepted for FDA Review: Capricor/Nippon Shinyaku
March 6, 2025
- Unexpected Demand Triggers Supply Curb for Eisai’s ALS Med Just 3 Months after Launch; Patients Urge Early Response
March 5, 2025
- Meiji Invests in French Vaccine Player Osivax
March 5, 2025
- Sumitomo Group Continues to Seek Best Partners for Pharma Biz
March 5, 2025
- Protagonist/Takeda’s Hematology Med Makes Mark in PIII
March 5, 2025
- Sato, Eisai to Wind Up Collab on Antifungal Nailin
March 5, 2025
- Nippon Kayaku Files Nuvation-Partnered ROS1 Inhibitor in Japan
March 5, 2025
- Enhertu Hits OS Goal in 2nd-Line Gastric Cancer Use
March 5, 2025
- Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA
March 5, 2025
- 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
- Novartis Bags Global Rights to Kyorin’s MRGPRX2 Antagonist
March 4, 2025
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Blackstone to Buy 60% Stake in Japan CRO CMIC
March 4, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
- ASKA Ties Up with Philippines’ MedChoice in Thyroid Space
March 4, 2025
- Japan’s 1st CGP Assay for Blood Cancer Now Available: Otsuka
March 4, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
- Nxera Assigns Cenerimod Rights in Japan, APAC to Viatris
March 3, 2025
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…